Publicacións en colaboración con investigadores/as de Universidade da Coruña (47)

2024

  1. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

2023

  1. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence

    Pharmaceutics, Vol. 15, Núm. 11

  2. NEmecum: digital tool for assisting in the prescription and dispensing of enteral nutrition formulas and infant preparations

    Nutricion Hospitalaria, Vol. 40, Núm. 5, pp. 924-933

  3. Outpatient parenteral antimicrobial therapy with continuous infusion of meropenem: A retrospective analysis of three years of clinical experience

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 6, pp. 321-328

  4. Telemedicine and severe asthma in our environment: Views on the experience of professionals and suggestions to make it a reality

    Open Respiratory Archives, Vol. 5, Núm. 3

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  3. Intensificación de Ustekinumab en enfermedad de Crohn: Revisión sistemática

    Ars pharmaceutica, Vol. 63, Núm. 4, pp. 345-354

  4. Microbiome in Immune-Mediated Uveitis

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

2021

  1. EXPERIENCE OF OBETICHOLIC ACID USE IN THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS IN A SMALL GROUP OF PATIENTS

    European Journal of Clinical Pharmacy, Vol. 23, Núm. 4, pp. 239-243

  2. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 1, pp. 16-21

  3. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases

    Journal of Clinical Pharmacy and Therapeutics, Vol. 46, Núm. 4, pp. 918-926

  4. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches

    Farmacia Hospitalaria, Vol. 45, pp. 11-37

2020

  1. Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway

    International Immunopharmacology, Vol. 89

  2. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

    Journal of Medical Virology, Vol. 92, Núm. 12, pp. 3488-3498

  3. Fingolimod in multiple sclerosis: Profile of use in habitual practice

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 6, pp. 346-349

  4. Flux-based assay for the identification of autophagy modulators for osteoarthritis

    Journal of Visualized Experiments, Vol. 2020, Núm. 161, pp. 1-14

  5. Pharmacogenomics and cardiovascular disease: Where are we and where do we go from here?

    Arquivos Brasileiros de Cardiologia, Vol. 115, Núm. 4, pp. 690-700

  6. Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae

    Biomedicine and Pharmacotherapy, Vol. 130

  7. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital

    Journal of Dermatological Treatment, Vol. 31, Núm. 7, pp. 698-701